NVIDIA's BioNeMo Bets Big on Drug Discovery as Specialized AI Rivals Emerge
NVIDIA is aggressively positioning its BioNeMo platform as the default AI infrastructure for pharmaceutical R&D, backed by high-profile partnerships with Thermo Fisher and Eli Lilly. A parallel surge of specialized biotech AI platforms from startups including Natera, Basecamp Research, and Owkin signals a maturing ecosystem that is reshaping valuations across semiconductor and healthtech equities. Investors are now weighing whether NVIDIA captures platform-layer dominance or whether a fragmented
ViaNews Editorial Team (Markets)•